FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Suprapapillary stent-by-stent deployment using slim fully covered metal stents versus plastic stents for unresectable malignant hilar biliary obstruction (SBSFLUX Trial): protocol for a multicenter randomized controlled trial. PMID 42002818 · Trials · 2026-Apr-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial. PMID 41774886 · J Clin Oncol · 2026-Apr-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. PMID 41747202 · J Clin Oncol · 2026-Apr-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial. PMID 41863180 · Vaccine · 2026-Apr-19 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studies. PMID 41855648 · Vaccine · 2026-Apr-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes, Moderators, and Predictors in Online Mindfulness-Based Cognitive Therapy for People With Cancer: Secondary Analysis of a Randomized Controlled Trial. PMID 41996463 · J Med Internet Res · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Probiotics on the Clinical Outcome and Inflammatory Response in Gastric Cancer Surgery: A Double Blinded Randomized Control Trial. PMID 41996041 · J Gastrointest Cancer · 2026-Apr-17 Study is a randomized trial in gastric cancer but is excluded because it does not involve a drug-containing intervention (probiotics are not a drug) and its primary endpoints are postoperative recovery metrics, not oncology time-to-event efficacy outcomes like OS or PFS. Phase is not stated. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intravenous Thrombolysis at Primary Stroke Centers Versus Comprehensive Stroke Centers: Analysis From the AcT Trial. PMID 41992950 · Can J Neurol Sci · 2026-Apr-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol. PMID 41992146 · BMC Cancer · 2026-Apr-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Oral selective estrogen receptor degraders in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis. PMID 41991764 · Breast Cancer Res Treat · 2026-Apr-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. PMID 41453117 · Br J Dermatol · 2026-Apr-17 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. PMID 41991782 · Patient · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease. PMID 41985133 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Asundexian for Secondary Stroke Prevention. PMID 41985132 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Ianalumab plus Eltrombopag in Immune Thrombocytopenia. PMID 41363800 · N Engl J Med · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy. PMID 42003280 · Cancer · 2026-Apr-15 The study is a Phase 2 randomized trial in oncology patients with a drug intervention, but it does not meet the definitive phase requirement (Phase III/IIIb or Phase II/III) and does not report a time-to-event efficacy endpoint, which are required for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. PMID 41986386 · Nat Commun · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Protocol of a randomised controlled trial: comparing the safety and efficacy of two methadone conversion strategies in Chinese patients with cancer pain receiving high-dose opioids. PMID 41985948 · BMJ Open · 2026-Apr-15 This is a clinical trial protocol (not a results report) for a randomized trial in cancer pain. While it involves oncology patients, human subjects, randomization, and a drug intervention, it does not present primary or secondary results. The primary efficacy endpoint is time to stable analgesia (not a time-to-event survival endpoint like OS/PFS). No Kaplan-Meier or HR data are reported. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial. PMID 41983724 · Ann Surg · 2026-Apr-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors. PMID 41591997 · Clin Cancer Res · 2026-Apr-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials. PMID 41985293 · Braz J Otorhinolaryngol · 2026-Apr-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol. PMID 41981510 · BMC Cancer · 2026-Apr-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Developing Transdiagnostic Single-Session Interventions for University Students Experiencing Disordered Eating: A Mixed-Method Co-Design Study. PMID 41978984 · Int J Eat Disord · 2026-Apr-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma. PMID 42074119 · Int J Mol Sci · 2026-Apr-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 42073552 · Cancers (Basel) · 2026-Apr-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. PMID 42042817 · Vaccines (Basel) · 2026-Apr-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial. PMID 41994955 · Clin Infect Dis · 2026-Apr-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of prevention of postoperative pulmonary complications with penehyclidine inhalation on long-term outcomes in high-risk patients: follow-up of a randomized trial. PMID 41973092 · J Anesth · 2026-Apr-13 The study is excluded because the drug intervention (penehyclidine) is not an oncology therapeutic agent; it is a perioperative supportive care measure aimed at preventing pulmonary complications, not treating the underlying malignancy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical value of intraoperative frozen section examination-assisted strategy in prostate biopsy: a comparative study of diagnostic efficiency and clinical practicality. PMID 41968340 · BMC Cancer · 2026-Apr-13 Study is a randomized, prospective, human oncology (prostate cancer) trial with original results. However, it is not a Phase III/IIIb or Phase II/III trial (phase not specified but appears to be a diagnostic study, not a definitive drug trial). It lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. It evaluates a diagnostic procedure (biopsy strategy), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Effect of electroacupuncture on intestinal function after laparoscopic colorectal cancer surgery]. PMID 41987441 · Zhongguo Zhen Jiu · 2026-Apr-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| [Effects of electroacupuncture on gastrointestinal dysfunction and serum metabolites in postoperative patients with gastric cancer]. PMID 41987440 · Zhongguo Zhen Jiu · 2026-Apr-12 The study is an oncology RCT in humans but is ineligible because the intervention is non-drug (electroacupuncture) and it lacks a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome. PMID 42042323 · Infect Dis Rep · 2026-Apr-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. PMID 41965705 · Arthritis Res Ther · 2026-Apr-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Expiratory Muscle Strength Training in Head and Neck Cancer Survivors With Radiation-Associated Dysphagia: Results of a Pilot Prospective Trial. PMID 41964362 · Head Neck · 2026-Apr-11 The record describes a single-arm pilot study of a non-drug intervention (expiratory muscle strength training) in head and neck cancer survivors. It lacks randomization, a drug intervention, and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study. PMID 41793964 · Vaccine · 2026-Apr-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Adenovirus type 5 vector-based COVID-19 vaccine does not increase the likelihood of HIV infection. PMID 41785679 · Vaccine · 2026-Apr-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY study. PMID 41967478 · Mod Rheumatol · 2026-Apr-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 study results for oral PCSK9 inhibition with enlicitide. PMID 41966715 · Med · 2026-Apr-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications. PMID 41963635 · Clin Transl Oncol · 2026-Apr-10 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study. PMID 41961227 · Jpn J Ophthalmol · 2026-Apr-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cardiac biomarkers in patients with renal cell carcinoma treated with immune checkpoint inhibitors. PMID 41912436 · Oncologist · 2026-Apr-10 The record is from a randomized Phase III oncology trial with a drug intervention, but the reported analysis focuses on cardiac biomarkers and safety, not a primary or key secondary time-to-event efficacy endpoint like OS or PFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. PMID 41734362 · J Clin Oncol · 2026-Apr-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bayesian adaptive randomization in the I-SPY2 sequential multiple assignment randomized trial. PMID 42053379 · Biometrics · 2026-Apr-09 The record describes the I-SPY2 SMART as a Phase 2 platform trial, not Phase III/IIIb. It is a methodology paper presenting a Bayesian adaptive randomization scheme, not a primary report of trial results with a time-to-event efficacy endpoint. The primary endpoint is pathological complete response (pCR), which is not a time-to-event outcome (OS, PFS, DFS, etc.). The intervention involves novel agents, but the paper focuses on the trial design and randomization algorithm, not on reporting specific drug intervention efficacy results. Therefore, it fails multiple key eligibility criteria: it is not a Phase III trial, lacks a time-to-event endpoint, is not a drug intervention efficacy result report, and is not an original formal trial result. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial. PMID 41966308 · J Hepatol · 2026-Apr-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial). PMID 41962942 · BMJ · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study. PMID 41956546 · J Immunother Cancer · 2026-Apr-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Survival after breast-conserving surgery and radiotherapy versus mastectomy: propensity score analyses within a randomized anaesthesiology trial. PMID 41954954 · Br J Surg · 2026-Apr-09 The record is a secondary analysis of survival outcomes from a randomized trial that compared anesthesia types, not a drug intervention. While the cohort is from a randomized trial and the endpoints are time-to-event efficacy outcomes (OS, BCSS), there is no drug-containing intervention, and the trial is not a Phase III/IIIb or Phase II/III oncology drug trial. Therefore, it does not meet the core eligibility criterion of a drug intervention in an oncology Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches. PMID 41642077 · Jpn J Clin Oncol · 2026-Apr-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancer. PMID 41543049 · Jpn J Clin Oncol · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of apalutamide in Asian patients with metastatic castration-sensitive prostate cancer: Bayesian reanalysis of the TITAN trial. PMID 41450247 · Jpn J Clin Oncol · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |